Niger
Tuberculosis profile
| High HIV burden |
Population  2012 17 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.8 (1.2–5.1) 16 (6.8–30)
Mortality (HIV+TB only) 0.62 (0.53–0.74) 3.6 (3.1–4.3)
Prevalence  (includes HIV+TB) 28 (14–48) 166 (83–277)
Incidence  (includes HIV+TB) 18 (15–21) 104 (86–124)
Incidence (HIV+TB only) 1.9 (1.5–2.2) 11 (8.9–13)
Case detection, all forms (%) 62 (52–75)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 6 848 (64) Relapse 347 (61)
Smear-negative 1 989 (19) Treatment after failure 133 (24)
Smear-unknown / not done 0 (0) Treatment after default 85 (15)
Extrapulmonary 1 689 (16) Other 0 (0)
Other 116 (1)      
Total new 10 642   Total retreatment 565  
           
Other (history unknown) 0        
Total new and relapse 10 989   Total cases notified 11 207  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 3.1    
Age < 15 88    
Laboratories 2012
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 80   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 78  
Retreatment 76  
TB/HIV 2012 Number (%)
TB patients with known HIV status 5 166 (46)
HIV-positive TB patients 431 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 135 (31)
HIV-positive TB patients on antiretroviral therapy (ART) 69 (16)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
160 (9–300) 110 (42–180)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 35 (6%) 35
Laboratory-confirmed MDR-TB cases 0 35 35
Patients started on MDR-TB treatment     77
Financing TB control 2013
National TB programme budget (US$ millions) 1.5
% Funded domestically 76%
% Funded internationally 24%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data